Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat. - Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009160

Enrollment

240

Registered

2012-10-22

Start date

2012-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease patients with hyperuricemia

Interventions

Control group(nutrition education) Febuxostat group(febuxostat+nutrition education)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)7.0mg/dl<uric acid levels<9.0mg/dl 2)Patients with ischemic heart disease 3)30ml/min<eGFR<90ml/min

Exclusion criteria

Exclusion criteria: 1)Patients with severe renal injury (eGFR<30ml/min) 2)Patients with severe liver injury 3)Patients with severe heart failure (NYHA Class4) 4)Patients with acute myocardial infarction within three months 5)Ineligible patients for any other reasons

Design outcomes

Primary

Measure	Time frame
Changes of estimated glomerular filtration rate(eGFR) between two groups( control group and medicated group).	—

Secondary

Measure	Time frame
1)Changes of eGFR between each two groups(control group and medicated group). 2)Changes of uric acid levels, ratio of achiving less than 6.0mg/dl of uric acid levels, changes of microalbuminuria/creatinine, changes of creatinene clearance, changes of C cystatin levels 3)Death, cardiovascular events(acute myocardial infarction, target vessel revascularization, new onset angina pectoris, congestive heart failure, cerebral infarction)	—

Measure

Time frame

1)Changes of eGFR between each two groups(control group and medicated group). 2)Changes of uric acid levels, ratio of achiving less than 6.0mg/dl of uric acid levels, changes of microalbuminuria/creatinine, changes of creatinene clearance, changes of C cystatin levels 3)Death, cardiovascular events(acute myocardial infarction, target vessel revascularization, new onset angina pectoris, congestive heart failure, cerebral infarction)

—

Countries

Japan

Contacts

Public ContactYuji Sakanoue

Higashisumiyoshi Morimoto Hospital Department of Cardiovascular Medicine

yujisaka@kcn.ne.jp06-6606-0010

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026